Courage Against Cancer
At Courage Against Cancer (CAC), we believe patients deserve evidence-based answers to the pillar article’s primary question — not dismissal, and not hype. Oncologist caution around fenbendazole in 2026 is rooted in specific clinical and regulatory reasoning, not ignorance of the research.
No evidence supports that natural remedies alone can cure colorectal cancer. While lifestyle changes and complementary approaches may support overall wellness alongside medical treatment, surgery and/or chemotherapy remain the evidence-based treatments recommended by oncologists.
The article discusses an Expression of Concern issued by Anticancer Research regarding the Hulscher et al. study on ivermectin and mebendazole. It highlights data verifiability issues, the authors’ conflicts of interest tied to The Wellness Company, and how this study differs from credible cancer research, ultimately urging caution for patients evaluating such claims.
Courage Against Cancer clarifies that ivermectin lacks validated clinical evidence as a cancer treatment despite preclinical interest. Major oncology institutions do not endorse it, emphasizing the importance of rigorous evidence-based evaluations. Patients are encouraged to discuss concerns with their oncologists and critically assess claims surrounding off-label treatments.
Courage Against Cancer emphasizes the importance of personalized cancer treatment plans, tailored based on cancer type, stage, and individual patient factors. This guide details various treatment modalities, including chemotherapy, radiation, immunotherapy, hormone therapy, and stem cell transplants, while encouraging patients to engage with their healthcare teams for informed decisions.
Courage Against Cancer emphasizes the importance of distinguishing between the registered trial NCT05318469 and the controversial Hulscher et al. 2026 study. The former aims to assess ivermectin’s safety and efficacy for metastatic triple-negative breast cancer under rigorous oversight, while the latter lacks validated endpoints and ethical scrutiny. Valid results are pending.
Courage Against Cancer clarifies the distinction between the legitimate preclinical research conducted by the NCI on ivermectin and the controversial Hulscher observational study. The latter’s findings are compromised due to bias and conflicts of interest. Conflating the two may mislead patients, potentially exploiting their vulnerability and delaying effective treatments.
Courage Against Cancer critiques the methodology of the Hulscher et al. study on cancer treatment, emphasizing the weaknesses of observational design and self-reported outcomes. It highlights issues like lack of randomization, potential bias, and conflicts of interest, stressing that results cannot reliably inform clinical decisions and urging patients to consult oncologists about research before acting.